Novo Nordisk has recently launched its premium long acting insulin Levemir (insulin detemir) in Bangladesh, which is designed to control blood sugar as well as reducing weight gain more effectively.
The launching ceremony was held at a local hotel in the city. Professor A K Azad Khan, President, Diabetic Association of Bangladesh and Professor Hajera Mahtab, Member National Council, BADS and Chairman of Board of Management, BIRDEM, Mr Melvin Oscar D’souza, Mnaging Director ROI, Mr. A. Rajon Kumar, Managing Director of Novo Nordisk Pharma Pvt. Ltd., Bangladesh were present on the occasion.
Mr. A. Rajon Kumar said, “The introduction of Levemir in Bangladesh now completes the portfolio of our modern insulin portfolio in the country.”
Levemir is a long-acting modern insulin analogue that covers the body’s basal insulin need very effectively. It is released gradually for a longer period up to 24 hours duration of action with a sigle daily dose, which is a great boon for the patients constantly threatened by nocturnal hypoglycemia. It is released gradually for a longer period and therefore entails less fluctuation in blood sugar level.
It has several other benefits like less nocturnal hypoglycaemia and less weight gain and hence it gives better outcome for obese diabetic patients and those at risk of obesity.
Prof. Azad told that the patients in this country will be beneficial to a great extent to have the insulin available at local market. He also urged the company to reduce the price of the insulin.
Levemir injections can be easily managed with prefilled insulin Flex-pen.
Source: The Daily Star, November 22, 2008